Jonah Feldman

A first-in-human trial of the antibody-drug conjugate is planned for later this year.

Timothy Hembree, DO, PhD, discusses the benefits to patients and physicians seen with an AI-supported virtual care system implemented at Moffitt Cancer Center.

Experts discuss their ASCO presentations on 3 rare disease states: uveal melanoma, mucosal melanoma, and Merkel cell carcinoma.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

FBEM conditioning in ALL alloHSCT yields 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Randomization of 864 patients showed Tal-DP and Tal-D significantly improved IRC-assessed PFS vs DPd (HR 0.28 and 0.33), meeting interim superiority boundaries. Benefit remained consistent across key subgroups, including first relapse lenalidomide-refractory disease, prior daratumumab exposure, ISS stage III, high-risk cytogenetics, and soft-tissue plasmacytomas.

Routine-practice recipients were older and heavily pretreated, with 85% triple-class exposure, 55% penta-drug exposure, 27% high-risk cytogenetics, and 57% requiring bridging therapy. Cilta-cel achieved deep responses in the registry cohort, yielding 87% ORR, 75% ≥VGPR, and 12‑month PFS/OS of 73%/85% despite 70% comorbidity prevalence.

Talquetamab plus daratumumab with or without pomalidomide markedly improved 2-year PFS and ≥CR rates versus DPd, supporting GPRC5D-directed bispecific combinations as first-relapse standard. Achieving ≥PR to bridging therapy before cilta-cel predicted superior 30-month PFS/OS across cytogenetic risk; responders had no parkinsonism signal, while infections dominated nonrelapse mortality in nonresponders.

FAC-HCT combines HCT-FS frailty category, chronological age, and HCT-CI into a point-based score defining low (0–5), intermediate (5.5–10), and high (>10) risk. Two-year overall survival separated consistently across cohorts: 79/63/44% in training and 75/62/38% in external validation for low/intermediate/high risk, respectively.

Susan Bal, MD, discusses outcomes with arlo-cel, a GPRC5D-targeted CAR T product in relapsed/refractory multiple myeloma.